Inozyme Pharma (INZY) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Inozyme Pharma in October 2026.
Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics that target the pyrophosphate (PPi)-Adenosine Pathway, a key regulator of bone health and blood vessel function. Its lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, ENPP1 fusion protein that is designed to increase PPi and adenosine, to enable the potential treatment of multiple diseases caused by deficiencies in these molecules. The Company is conducting clinical trials of INZ-701 for the treatment of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency, ATP-Binding Cassette in the C6 family (ABCC6) Deficiency, and calciphylaxis. The Company also plans to investigate the potential of a next generation INZ-701 molecule to address posterior longitudinal ligament (OPLL).
Inozyme Pharma (INZY) Stock Forecast
Analyst price target, next 12 months
$19.00
+380.4% vs today's $3.96
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Inozyme Pharma have a consensus 12-month target of $19.00, above the current price of $3.96.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 28 May 2025.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Inozyme Pharma's stock with a target price of $18.63, indicating potential growth.
Financial Health
Inozyme Pharma is generating solid cash flow and maintains a reasonable book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.